X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.98 +1.49%

+$0.06 today

Market cap
$304.30M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 0.64M

Average 0.40M

XFOR Operating Cash Flow

Cash generated by the company's core business operations during the period.

X4 Pharmaceuticals, Inc.NASDAQ: XFOR

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $19.6M (cash outflow) rose 58.5% year over year, ahead of the -15.3% change in trailing-twelve-month operating cash flow. Sequentially, it rose 26.2% from the prior quarter. Over 3 fiscal years it compounded at +3.6% a year.

Context

  • Operating cash flow amounted to 243.8% of revenue in FY2025, down 4875.5 pp from a year earlier.
  • Operating cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +58.5% holds above the trailing-twelve-month pace of -15.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.6M+26.2% QoQ
Last fiscal yearDec 2025
-$85.62M-34.6% YoY
LTMMar 2026
-$92.85M-15.3% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.5%——
1 year-34.6%——
3-year CAGR+3.6%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(85.62M) USD
Year-over-year change
+34.6%

Operating Cash Flow vs competitors

How XFOR compares with its peers on the latest reported figures

  • XFOR's LTM Mar 2026 operating cash flow of $92.85M is the largest of the 4 companies compared; the peer median is $50.76M.
  • Its year-over-year change of -15.3% is the 2nd highest of 4, against a peer median of -41.4%.
  • Operating cash flow amounts to 1030.1% of revenue for XFOR, versus a peer median of 39.1%.
XFOR Competitors Peer median
Operating Cash Flow for XFOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$92.85M -15.3%+3.6%1030.1%
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$59.11M -51.8%-20.4%39.1%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$50.76M -2.7%+24.4%—
INMBINmune Bio, Inc.LTM Mar 2026$19.17M -41.4%-0.2%—
Peer median (excluding XFOR) $50.76M-41.4%-0.2%39.1%

Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(88.7M)(93.87M)(101.17M)(37.45M)(79.2M)
Depreciation & Amortization1.89M513K419K796K1.28M
Deferred Income Tax00000
Stock-Based Compensation05.2M8.69M8.2M4.3M
Change in Working Capital(1.5M)5.74M344K2.68M(2.58M)
Accounts Receivables000(1.07M)497K
Inventory000(2.82M)(1.66M)
Accounts Payables1.17M3.43M1.23M(286K)(2.98M)
Other Working Capital(2.66M)2.31M(890K)6.85M1.57M
Other Non-Cash Items17.4M5.32M(4.8M)(105.13M)(9.42M)
Operating Cash Flow(70.91M)(77.1M)(96.51M)(130.9M)(85.62M)
Capital Expenditures(615K)(103K)(60K)(7.33M)(3M)
Acquisitions (Net)00000
Purchases of Investments00(16.82M)(57.13M)(63.39M)
Sales of Investments002M26.45M74.54M
Other Investing Activities00098M0
Investing Cash Flow(615K)(103K)(14.88M)66.99M8.15M
Debt Repayment0(795K)20.44M20M0
Common Stock Issued76.25M122.63M60M294K238.53M
Common Stock Repurchased(2M)0000
Dividends Paid00000
Other Financing Activities0(4.61M)8.08M098K
Financing Cash Flow74.25M117.23M88.52M20.29M238.63M
Effect of Forex Changes90K(105K)99K(156K)213K
Net Change in Cash2.82M39.92M(22.78M)(43.77M)161.38M
Free Cash Flow(71.52M)(77.21M)(96.57M)(138.23M)(88.62M)

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.